Key result
Fetal myocardial hypertrophy was significantly more severe at term in poorly controlled diabetic pregnancies compared to controls, and predicted neonatal morbidities like hypoglycemia.
Why the study?
Data from India were sparse regarding whether fetal echocardiography among pregnant diabetics could help predict adverse perinatal or neonatal outcomes.
Does fetal echocardiography at term in diabetic pregnancies predict adverse neonatal outcomes?
Cohort (n=185)
No
Does fetal echocardiography at term in diabetic pregnancies predict adverse neonatal outcomes?
Fetal echocardiography at term in diabetic pregnancies reveals myocardial hypertrophy that correlates with suboptimal glycemic control and predicts adverse neonatal outcomes like hypoglycemia.
Answers are grounded in this paper and cite their sources.
Fetal echo at term may flag neonatal risk in diabetic pregnancies; leaves open whether routine screening improves outcomes.
There is sparse Indian data on whether fetal echocardiography among pregnant diabetics would be useful to predict adverse perinatal/neonatal outcome. OBJECTIVES: To study fetal cardiac changes in diabetic mothers and non-diabetic controls from 24 weeks gestation until the neonatal period; correlate them with maternal glycemic control; study their implications on adverse perinatal/neonatal outcome. METHODOLOGY: Prospective observational cohort study. Pregnant diabetics (17 overt, 66 gestational) recruited beyond 24 weeks, divided as well (39) and poorly (44) controlled, based on American Diabetes Association 2016 criteria. Controls were 102 healthy non-diabetic pregnancies. Fetal echocardiography performed at weeks 24-32, 32-36, >37, and between 4 and 7 days on neonates. The thickness of Interventricular septum (IVS), Right Ventricle (RV), and Left ventricle (LV) assessed with M mode. E/A ratio across Tricuspid/Mitral valves and Tei index determined. TDI(Tissue Doppler imaging) used to assess tissue annular velocities across IVS, RV, and LV. Maternal glycemic control and various perinatal/neonatal adverse outcomes were recorded. RESULTS: Significant myocardial hypertrophy seen among fetuses of diabetic mothers versus controls, most severe at term among the poorly controlled diabetics. Structural changes persisted in the neonate. At term, fetal myocardial dysfunction was evident among diabetic pregnancies only as poor annular systolic velocity across IVS, RV using TDI. However, Tissue Doppler changes could not predict adverse perinatal/neonatal outcome. Myocardial dysfunction could not be demonstrated in the neonates. Myocardial hypertrophy at term was a surrogate marker for suboptimal glycemic control, and it could predict important neonatal morbidities like hypoglycaemia, hyperbilirubinemia, prolonged NICU stays, and persistent foetal cardiac shunts. CONCLUSION: Our study shows a significant association between fetal myocardial hypertrophy and maternal glycemic control among GDM pregnancies. There also seems to be an association between fetal myocardial hypertrophy and some of the adverse perinatal events including hypoglycemia. However these newborns were not found to have clinically relevant cardiac comorbidities even though there was significant septal hypertrophy in utero.
No takes yet. Share an insight, caveat, or question.
Tejaswi et al. (2020) conducted a cohort in Gestational diabetes mellitus (n=185). Maternal diabetes vs. Healthy non-diabetic pregnancies was evaluated on Interventricular septum thickness (IVSD) at >37 weeks gestation (mm) (p=<0.001). Fetal myocardial hypertrophy was significantly more severe at term in poorly controlled diabetic pregnancies compared to controls, and predicted neonatal morbidities like hypoglycemia.
Synapse has enriched 10 related papers. Consider them for comparative context: